It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

On the heels of a production-tinged executive order earlier this month, the Trump administration is doubling down on efforts ...

On Nov. 9, 2020, Pfizer and partner BioNTech announced that the vaccine had met the first effectiveness bar in a key study.

The FDA has lifted its 19-month clinical hold on vaginal yeast infection drug Brexafemme (ibrexafungerp), according to the ...

With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an ...

Just a few weeks after Omnicom announced in early December its plans to acquire fello | Craig Romanok, chief marketing ...

WuXi Biologics is giving CDMO Terumo the keys to its site in Leverkusen, Germany, with a 150 million euros ($167 million) ...

A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...